Age‐related disability in multiple sclerosisMaría Trojano, Paolo Livrea, Maria Liguori et al.|Annals of Neurology|2002Cited by 184
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypesCarlo Avolio, María Trojano, Maddalena Ruggieri et al.|Journal of Neuroimmunology|2003Cited by 177
Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MSMaría Trojano, Paolo Livrea, Grazia Maria Liuzzi et al.|Neurology|1999Cited by 127
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern ItalyMaría Trojano, Maria Liguori, Damiano Paolicelli et al.|Multiple Sclerosis Journal|2003Cited by 67
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Massimiliano Mirabella et al.|Journal of Neurology|2018Cited by 54